SCHEMBL1414643

SCHEMBL1414643

COc1ccc(-c2c3cccc(Cl)c3nn2Cc2ccccc2F)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 8/20 0.48
NR1H3 Q13133 8/20 0.48
NR1I2 O75469 2/20 0.45
NR3C1 P04150 2/20 0.45
NPBWR1 P48145 6/20 0.44
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
P2RX7 Q99572 2/20 0.40
AR P10275 1/20 0.39
RXRA P19793 1/20 0.39
ROCK2 O75116 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407762 0.92 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1NPBWR1
SCHEMBL1407447 0.92 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1NPBWR1
SCHEMBL1407454 0.90 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1NPBWR1
SCHEMBL1407812 0.87 NR1H2 (0.43) NR1H2NR1H3NPBWR1ALDH1A1
SCHEMBL1407321 0.86 NR1H2 (0.47) NR1H2NR1H3NR1I2NR3C1NPC1
SCHEMBL1407384 0.85 KMT2A (0.48) NR1H2NR1H3NPBWR1ALDH1A1MAPT
SCHEMBL1407455 0.84 NR1H2 (0.45) NR1H2NR1H3ALDH1A1
SCHEMBL1408297 0.83 NR1H2 (0.43) NR1H2NR1H3NR1I2NR3C1MAPT
SCHEMBL1408459 0.82 NR1H2 (0.48) NR1H2NR1H3NR1I2NR3C1NPBWR1
SCHEMBL1407475 0.82 NR1H2 (0.46) NR1H2NR1H3ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP disclosed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NR1I2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.